/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

Zymeworks Inc Share Price Today: Live Updates & Key Insights

Zymeworks Inc share price today is $23.33, up -7.6%. The stock opened at $24.71 against the previous close of $25.14, with an intraday high of $24.71 and low of $23.12.

Zymeworks Inc Share Price Chart

style
pb-0

Zymeworks Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0

Zymeworks Inc Share Price Performance

$23.33 -0.076(-7.6%) ZYME at 13 Mar 2026 04:01 PM Biotechnology
Lowest Today 23.12
Highest Today 24.71
Today’s Open 24.71
Prev. Close 25.14
52 Week High 28.49
52 Week Low 9.03
Day’s Range: Low 23.12 High 24.71
52-Week Range: Low 9.03 High 28.49
1 day return -
1 Week return -3.56
1 month return +2.83
3 month return -10.44
6 month return +45.75
1 year return +85.4
3 year return +181.69
5 year return -31.84
10 year return -

Zymeworks Inc Institutional Holdings

EcoR1 Capital, LLC 31.15

Rubric Capital Management LP 7.80

BlackRock Inc 5.41

Morgan Stanley - Brokerage Accounts 5.40

Bvf Inc 5.34

Redmile Group, LLC 5.02

HBM Healthcare Investments AG Ord 3.40

Vanguard Group Inc 3.16

Perceptive Advisors LLC 2.83

UBS Asset Mgmt Americas Inc 2.32

Siren, L.L.C. 2.28

Vanguard Total Stock Mkt Idx Inv 2.22

Blackstone Inc 2.19

Deutsche Bank AG 2.09

iShares Russell 2000 ETF 1.63

Dimensional Fund Advisors, Inc. 1.57

Nextech Invest, Ltd. 1.51

Millennium Management LLC 1.50

TANG CAPITAL MANAGEMENT LLC 1.49

State Street Corp 1.47

Capricorn Fund Managers Ltd 1.39

BNP Paribas US Small Cap ClassicC 1.26

Vestal Point Capital LP 1.17

Xtrackers S&P 500 Swap ETF 1C 1.03

Arrowstreet Capital Limited Partnership 0.95

Xtrackers S&P 500 2xLev Dly Swap ETF 1C 0.85

iShares Biotechnology ETF 0.73

BNP Paribas Health Cr Innovtr Cl Cap 0.66

Fidelity Small Cap Index 0.66

Nuveen Quant Small Cap Equity R6 0.57

iShares Russell 2000 Growth ETF 0.56

Fidelity Small Cap Growth 0.50

State St Russell Sm/Mid Cp® Indx SL Cl I 0.45

MEDICAL BioHealth EUR Acc 0.36

DFA US Small Cap I 0.34

Vanguard Russell 2000 ETF 0.32

BlackRock Advantage Small Cap Core Instl 0.30

Dimensional US Small Cap ETF 0.26

Invesco MSCI World ETF 0.25

Fidelity Small Cap Growth K6 0.25

Zymeworks Inc Market Status

Strong Buy: 7

Buy: 1

Hold: 2

Sell: 0

Strong Sell: 0

Zymeworks Inc Fundamentals

Market Cap 1867.97 M

PB Ratio 6.957

PE Ratio 0.0

Enterprise Value 1657.44 M

Total Assets 346.53 M

Volume 681239

Zymeworks Inc Company Financials

Annual Revenue FY23:461579000 461.6M, FY22:412482000 412.5M, FY21:26680000 26.7M, FY20:38951000 39.0M, FY19:29544000 29.5M

Annual Profit FY23:null 0.0M, FY22:412482000 412.5M, FY21:26680000 26.7M, FY20:38951000 39.0M, FY19:29544000 29.5M

Annual Net worth FY23:205239000 205.2M, FY22:124341000 124.3M, FY21:-211843000 -211.8M, FY20:-180552000 -180.6M, FY19:-145437000 -145.4M

Quarterly Revenue Q3/2025:27614000 27.6M, Q2/2025:48726000 48.7M, Q1/2025:27110000 27.1M, Q3/2024:16000000 16.0M, Q2/2024:19243000 19.2M

Quarterly Profit Q3/2025:27614000 27.6M, Q2/2025:48726000 48.7M, Q1/2025:27110000 27.1M, Q3/2024:13337000 13.3M, Q2/2024:16714000 16.7M

Quarterly Net worth Q3/2025:-19602000 -19.6M, Q2/2025:2317000 2.3M, Q1/2025:-22636000 -22.6M, Q3/2024:-29850000 -29.9M, Q2/2024:-37686000 -37.7M

About Zymeworks Inc & investment objective

Company Information Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidates include Ziihera (zanidatamab-hrii), a bispecific antibody targeting HER2-expressing tumors; zanidatamab for the treatment of neoadjuvant populations, breast cancer, and other HER2-expressing cancers; Pasritamig, a bispecific T cell engager targeting human kallikrein 2 for the treatment monotherapy and castration resistant prostate cancer; ZW191, a clinical- antibody-drug conjugates (ADC) that targets folate receptor alpha expressing tumors, including ovarian, endometrial, and non-small cell lung cancers; ZW251, a clinical-stage ADC molecule for the treatment of glypican 3 expressing hepatocellular carcinoma; ZW220, an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer; ZW209, a novel TriTCE targeting Delta-like ligand 3 -expressing tumor cells for the treatment of solid tumors; and ZW1528, a bispecific molecule to treat chronic obstructive pulmonary disease. It has strategic partnerships and collaborations with Jazz Pharmaceuticals plc; Bristol- Myers Squibb company; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Merck Sharp & Dohme Research GmbH; and Janssen Biotech, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.

Organisation Biotechnology

Employees 264

Industry Biotechnology

CEO Mr. Kenneth H. Galbraith C.A.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow